Oyster Point Pharma, Inc. (OYST) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Oyster Point Pharma, Inc. (OYST) trades at $11.17 with AI Score 59/100 (Grade B). Oyster Point Pharma, Inc. was a commercial-stage biopharmaceutical company focused on ophthalmic disease therapies. It was acquired by Viatris Inc. Sector: Healthcare.
Price as of Jul 27, 2026 · Last analyzed: May 9, 2026Analyst Coverage for OYST: OYST does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OYST against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
OYST: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Oyster Point Pharma, Inc. (OYST) Healthcare & Pipeline Overview
Oyster Point Pharma, Inc., now a subsidiary of Viatris, developed and commercialized pharmaceutical therapies for ophthalmic diseases, primarily focusing on dry eye disease with its TYRVAYA product. The company targeted a significant unmet need in the U.S. market before its acquisition.
What Is the Investment Thesis for OYST?
Prior to its acquisition, Oyster Point Pharma presented a compelling investment thesis centered on TYRVAYA's potential to capture a significant share of the dry eye disease market. The novel mechanism of action, delivered via nasal spray, offered a differentiated approach compared to traditional eye drops. Key value drivers included increasing TYRVAYA prescription rates, expanding market access through strategic partnerships, and successful completion of the Phase II clinical trial for neurotrophic keratopathy. However, potential risks included competition from established dry eye therapies, regulatory hurdles, and the company's high operating expenses, reflected in a negative profit margin of -425.4%.
Based on FMP financials and quantitative analysis
OYST Key Highlights
- TYRVAYA is a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease.
- The company was developing TYRVAYA in Phase II clinical trial for the treatment of neurotrophic keratopathy.
- Gross Margin was reported at 93.8% indicating strong pricing power.
- The company was acquired by Viatris Inc. on January 3, 2023.
- Oyster Point Pharma, Inc. was incorporated in 2015.
Who Are OYST's Competitors?
OYST is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVR AlloVir, Inc. | $9.81 | +4.14% | $49.5M | 46 |
| MRK Merck & Co., Inc. | $130.76 | -0.24% | $323B | 86 |
| ABBV AbbVie Inc. | $261.23 | +0.72% | $462B | 80 |
| VRTX Vertex Pharmaceuticals Incorporated | $479.00 | +0.34% | $122B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $667.17 | +1.70% | $68.7B | 92 |
| ALNY Alnylam Pharmaceuticals, Inc. | $278.40 | +2.44% | $37.2B | 95 |
| RPRX Royalty Pharma plc | $58.90 | +0.12% | $25.3B | 81 |
| INCY Incyte Corporation | $118.87 | +1.02% | $24.0B | 99 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OYST's Key Strengths?
- Novel drug delivery method (nasal spray).
- Targeted treatment for dry eye disease.
- Phase II clinical trial for neurotrophic keratopathy.
- High gross margin (93.8%).
What Are OYST's Weaknesses?
- High operating expenses.
- Negative profit margin (-425.4%).
- Dependence on a single product (TYRVAYA).
- Limited market presence prior to acquisition.
What Could Drive OYST Stock Higher?
- Integration of Oyster Point Pharma's assets and pipeline into Viatris Inc.
- Continued commercialization of TYRVAYA by Viatris.
- Potential expansion of TYRVAYA's market reach under Viatris's leadership.
What Are the Key Risks for OYST?
- Negative return on equity (-73.0%) — the business is not currently generating profit on shareholder capital.
- Integration challenges following the acquisition by Viatris.
- Competition from other dry eye therapies.
- Regulatory setbacks.
- Dependence on the success of TYRVAYA.
What Are the Growth Opportunities for OYST?
- Expansion of TYRVAYA's Market Reach: Before acquisition, a significant growth opportunity for Oyster Point was expanding the market reach of TYRVAYA. This involved increasing awareness among eye care professionals and patients, securing favorable reimbursement coverage from payers, and potentially expanding into international markets. Capturing a larger share of the dry eye disease market, estimated to be worth billions of dollars annually, could drive substantial revenue growth. Timeline: Before acquisition by Viatris.
- Development of TYRVAYA for Neurotrophic Keratopathy: The successful completion of the Phase II clinical trial for TYRVAYA in the treatment of neurotrophic keratopathy represented another key growth opportunity. Neurotrophic keratopathy is a rare and debilitating corneal disease with limited treatment options. Positive clinical data and subsequent regulatory approval could open up a new market for TYRVAYA and establish Oyster Point as a leader in ophthalmic disease therapies. Timeline: Before acquisition by Viatris.
- Strategic Partnerships and Acquisitions: Oyster Point could pursue strategic partnerships or acquisitions to expand its product pipeline and market presence. Collaborating with other pharmaceutical companies or acquiring complementary assets could accelerate growth and diversify its revenue streams. This could involve licensing or acquiring new ophthalmic therapies or technologies. Timeline: Before acquisition by Viatris.
- Lifecycle Management of TYRVAYA: Implementing effective lifecycle management strategies for TYRVAYA could extend its market exclusivity and maximize its revenue potential. This could involve developing new formulations, dosages, or delivery methods, as well as securing additional patents to protect its intellectual property. Timeline: Before acquisition by Viatris.
- Expansion into New Ophthalmic Indications: Oyster Point could leverage its expertise in ophthalmic drug development to expand into new therapeutic areas beyond dry eye disease and neurotrophic keratopathy. This could involve targeting other common eye conditions, such as glaucoma, macular degeneration, or diabetic retinopathy. Timeline: Before acquisition by Viatris.
What Opportunities Does OYST Have?
- Expansion of TYRVAYA's market reach.
- Development of TYRVAYA for new indications.
- Strategic partnerships and acquisitions.
- Lifecycle management of TYRVAYA.
What Threats Does OYST Face?
- Competition from established dry eye therapies.
- Regulatory hurdles.
- Patent expiration.
- Pricing pressures.
What Are OYST's Competitive Advantages?
- Novel Mechanism of Action: TYRVAYA's unique nasal spray delivery and nicotinic acetylcholine receptor agonist mechanism of action differentiated it from traditional dry eye therapies.
- Intellectual Property Protection: Patents protecting TYRVAYA's composition of matter and method of use provided a degree of market exclusivity.
- Clinical Data: Positive clinical trial results supported the safety and efficacy of TYRVAYA, enhancing its credibility and market acceptance.
- First Mover Advantage: TYRVAYA was the first nasal spray approved for the treatment of dry eye disease, giving it a potential first-mover advantage.
What Does OYST Do?
Oyster Point Pharma, Inc. was founded in 2015 and headquartered in Princeton, New Jersey. The company focused on identifying, developing, and commercializing innovative pharmaceutical therapies to address unmet needs in the treatment of ophthalmic diseases. Its primary focus was on therapies for dry eye disease. Oyster Point's lead product, TYRVAYA (varenicline solution) nasal spray, is a nicotinic acetylcholine receptor (nAChR) agonist indicated for the treatment of the signs and symptoms of dry eye disease. TYRVAYA represented a novel approach to treating dry eye by activating the trigeminal nerve to stimulate natural tear production. In addition to TYRVAYA, Oyster Point was also developing the therapy for neurotrophic keratopathy, with the product in Phase II clinical trials. The company aimed to provide innovative solutions for patients suffering from various ophthalmic conditions. However, as of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc., integrating its assets and pipeline into Viatris's broader pharmaceutical portfolio.
What Products and Services Does OYST Offer?
- Developed and commercialized TYRVAYA (varenicline solution) nasal spray for dry eye disease.
- Focused on pharmaceutical therapies for ophthalmic diseases.
- Conducted clinical trials to evaluate the safety and efficacy of its product candidates.
- Sought regulatory approvals from the FDA for its therapies.
- Marketed and sold its products to eye care professionals and patients.
- Engaged in research and development to discover new ophthalmic therapies.
How Does OYST Make Money?
- Developed and commercialized prescription pharmaceutical products.
- Generated revenue through sales of TYRVAYA.
- Invested in research and development to expand its product pipeline.
- Partnered with distributors and pharmacies to ensure product availability.
What Industry Does OYST Operate In?
Oyster Point Pharma operated within the competitive ophthalmic pharmaceutical market, characterized by a growing prevalence of dry eye disease and an increasing demand for innovative treatment options. The market includes established players with existing dry eye therapies, as well as emerging companies developing novel approaches. Oyster Point differentiated itself through TYRVAYA's unique nasal spray delivery and mechanism of action. The acquisition by Viatris reflects the ongoing consolidation within the pharmaceutical industry, as larger companies seek to expand their portfolios and pipelines through strategic acquisitions.
Who Are OYST's Key Customers?
- Patients suffering from dry eye disease.
- Eye care professionals, including ophthalmologists and optometrists.
- Pharmacies and distributors that dispense and sell TYRVAYA.
- Hospitals and clinics that treat ophthalmic conditions.
ROE -73%Key Financial Metrics
Return on equity for Oyster Point Pharma, Inc. stands at -73.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -46.9%, showing how much profit it generates from its asset base. A current ratio of 7.47 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -35.9%, the inverse of the P/E and a quick read on earnings relative to price.
OYST Valuation & Market Position
Relative to its peer group, OYST's quantitative score of 59/100 is below the peer average of 80/100.
Company Profile
Oyster Point Pharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Princeton, US. The company is led by CEO Jeffrey Nau. OYST has traded publicly since 2019.
OYST Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Novel drug delivery method (nasal spray).
- Targeted treatment for dry eye disease.
- Phase II clinical trial for neurotrophic keratopathy.
- High gross margin (93.8%).
Bear Case
- High operating expenses.
- Negative profit margin (-425.4%).
- Dependence on a single product (TYRVAYA).
- Limited market presence prior to acquisition.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
OYST Latest News
-
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
benzinga · Nov 8, 2022
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · May 25, 2022
-
Earnings Scheduled For November 4, 2021
· Nov 4, 2021
-
Earnings Scheduled For May 6, 2021
· May 6, 2021
OYST Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OYST.
Price Targets
Wall Street price target analysis for OYST.
OYST MoonshotScore
What does this score mean?
The MoonshotScore rates OYST 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jeffrey Nau
CEO
Jeffrey Nau served as the CEO of Oyster Point Pharma, Inc. He has extensive experience in the pharmaceutical industry, with a focus on ophthalmology. Prior to joining Oyster Point, he held leadership positions at various pharmaceutical companies, where he was responsible for the development and commercialization of ophthalmic products. His background includes expertise in clinical development, regulatory affairs, and commercial strategy.
Track Record: Under Jeffrey Nau's leadership, Oyster Point Pharma successfully developed and launched TYRVAYA, the first nasal spray for the treatment of dry eye disease. He oversaw the company's clinical development programs, regulatory submissions, and commercialization efforts. He also led the company through its initial public offering and subsequent acquisition by Viatris Inc.
What Investors Ask About Oyster Point Pharma, Inc. (OYST) — Healthcare
What does the AI Score mean for OYST?
OYST holds an AI Score of 59/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Oyster Point Pharma, Inc. was a commercial-stage biopharmaceutical company focused on ophthalmic disease therapies. It was acquired by Viatris Inc. on January 3, 2023.
What does Oyster Point Pharma, Inc. do?
Oyster Point Pharma, Inc. was a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases. Its primary product was TYRVAYA (varenicline solution) nasal spray, indicated for the treatment of the signs and symptoms of dry eye disease. The company aimed to provide innovative solutions for patients suffering from various ophthalmic conditions before being acquired by Viatris Inc.
What do analysts say about OYST stock?
Prior to the acquisition by Viatris, analysts covering Oyster Point Pharma generally focused on the potential of TYRVAYA to capture a significant share of the dry eye disease market. Key valuation metrics included revenue growth projections, market penetration rates, and profitability forecasts. Growth considerations centered on the successful commercialization of TYRVAYA, expansion into new indications, and strategic partnerships.
What are the main risks for OYST?
The main risks for Oyster Point Pharma, prior to its acquisition, included competition from established dry eye therapies, regulatory hurdles, and the company's high operating expenses. Dependence on the success of TYRVAYA also posed a significant risk. Additionally, potential challenges related to manufacturing, marketing, and reimbursement could impact the company's financial performance. Integration risks following the acquisition by Viatris also represent a potential concern.
What is Oyster Point Pharma, Inc.'s drug pipeline status?
Oyster Point Pharma's primary focus was on TYRVAYA, which was approved for the treatment of dry eye disease. In addition to TYRVAYA, the company was developing the therapy in a Phase II clinical trial for the treatment of neurotrophic keratopathy. The pipeline was relatively focused, with TYRVAYA representing the core asset. The successful development and commercialization of TYRVAYA for additional indications was a key strategic priority before the acquisition.
How does Oyster Point Pharma, Inc.'s TYRVAYA differentiate itself from existing dry eye treatments?
TYRVAYA differentiates itself through its unique mechanism of action and nasal spray delivery. Unlike traditional eye drops that target tear film deficiencies, TYRVAYA is a nicotinic acetylcholine receptor agonist that stimulates natural tear production by activating the trigeminal nerve. The nasal spray delivery offers a convenient and non-invasive alternative to eye drops, potentially improving patient compliance and adherence.
What are the key factors to evaluate for OYST?
Oyster Point Pharma, Inc. (OYST) holds an AI score of 59/100 (moderate). Not financial advice.
How frequently does OYST data refresh on this page?
OYST's price was last updated on Jul 27, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven OYST's recent stock price performance?
Oyster Point Pharma, Inc. (OYST) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel drug delivery method (nasal spray). See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on data available up to the acquisition date of January 3, 2023. Current status reflects integration into Viatris Inc.